Retrospective cohort study shows hydroxyurea reduces vaso-occlusive crises in adults with sickle cell disease, highlighting safety and discontinuation issues.
Key Points
Hydroxyurea reduces vaso-occlusive crises by 56%, as shown in a cohort of 263 adults with sickle cell disease.
Patients experienced mild adverse events, with 27.3% discontinuing treatment primarily due to lack of awareness.
Retrospective analysis from January 2010 to July 2025 surveyed treatment impact on health outcomes in Quebec.
Education and adherence strategies are essential for maximizing therapeutic benefits from hydroxyurea use.